Illumina Inc. (ILMN) - 5i Research

Illumina Inc. (ILMN $94.66)
- $94.66 Cap: $14.98B
- View ILMN Profile
- View Questions on ILMN

{tplLang.businessdescription | toLang tLang}

{ profileData.description }

{tplLang.details | toLang tLang}

{tplLang.ceo | toLang tLang}

{profileData.profile.details.ceo}

{tplLang.employees | toLang tLang}

{profileData.profile.details.employees | numeraljs '0,0'}

{tplLang.issuetype | toLang tLang}

{profileData.profile.details.issuetype | asIssueType}

{tplLang.industryclassifications | toLang tLang}

{tplLang.sector | toLang tLang}

{profileData.profile.classification.sector}

{tplLang.industry | toLang tLang}

{profileData.profile.classification.industry}

{tplLang.toolname| toLang tLang}

There is no {tplLang.toolname| toLang tLang} currently available for {data.symbolstring}.

Illumina Inc. (ILMN $94.66)
- $94.66 Cap: $14.98B
- View ILMN Profile
- View Questions on ILMN

Q: Why is ILMN your favourite in Multiomic sequencing? And is this a good price point to start a position?

Read Answer Asked by Danielle on June 18, 2025

Illumina Inc. (ILMN $94.66)
- $94.66 Cap: $14.98B
- View ILMN Profile
- View Questions on ILMN
Pacific Biosciences of California Inc. (PACB $1.33)
- $1.33 Cap: $447M
- View PACB Profile
- View Questions on PACB
CRISPR Therapeutics AG (CRSP $56.09)
- $56.09 Cap: $4.84B
- View CRSP Profile
- View Questions on CRSP
Bio-Techne Corp (TECH $54.89)
- $54.89 P/E (TTM): 65.94X Cap: $9.04B
- View TECH Profile
- View Questions on TECH
10x Genomics Inc. (TXG $13.08)
- $13.08 Cap: $1.61B
- View TXG Profile
- View Questions on TXG

Q: Can you recommend stocks or ETFs in Multiomic sequencing

Read Answer Asked by Danielle on June 17, 2025

Gilead Sciences Inc. (GILD $113.18)
- $113.18 P/E (TTM): 23.59X Cap: $140.78B
- View GILD Profile
- View Questions on GILD
Illumina Inc. (ILMN $94.66)
- $94.66 Cap: $14.98B
- View ILMN Profile
- View Questions on ILMN
Intuitive Surgical Inc. (ISRG $483.12)
- $483.12 P/E (TTM): 70.44X Cap: $173.18B
- View ISRG Profile
- View Questions on ISRG
AbbVie Inc. (ABBV $195.22)
- $195.22 P/E (TTM): 80.78X Cap: $344.83B
- View ABBV Profile
- View Questions on ABBV
Eli Lilly and Company (LLY $762.33)
- $762.33 P/E (TTM): 60.22X Cap: $722.48B
- View LLY Profile
- View Questions on LLY
UnitedHealth Group Incorporated (DE) (UNH $237.77)
- $237.77 P/E (TTM): 10.45X Cap: $215.69B
- View UNH Profile
- View Questions on UNH
Novo Nordisk A/S (NVO $48.19)
- $48.19 P/E (TTM): 13.28X Cap: $363.68B
- View NVO Profile
- View Questions on NVO
BioMarin Pharmaceutical Inc. (BMRN $58.14)
- $58.14 P/E (TTM): 21.51X Cap: $11.27B
- View BMRN Profile
- View Questions on BMRN

Q: I am working on increasing my sector representation in Healthcare. I will shortly have filled a full position in ISRG, adding in this downturn. I have traded around UNH, and am planning to take it from a 1/2 to full position. I have 1/4 position in ILMN and do not think I should be topping it up; I perceive it to be risky. I need 2 more companies, or may need to take one or both of IRSG/UNH to more than a full position.

This provides me a surgical/instrumentation company and a service/product supplier. For diversity in the Healthcare space can you rank your preferred buys (with entry points) I'd appreciate 2 recommendations on the pharmaseuticals side and 2 on the biotech side, or as you may see that fits better.

While I am open US companies I do have a concern that the Trump administration will bring the DOGE and Executive Order train wrecks to health care. I would appreciate your views on this potential action and howe it may impact investment choice in the field.

Thanks as always,

Dave

Read Answer Asked by Dave on March 25, 2025